Boston, Massachusetts--(Newsfile Corp. - March 5, 2021) - The Thornton Law Firm announces that a class action lawsuit has been filed on behalf of investors of AstraZeneca PLC (NASDAQ: AZN). The case is currently in the lead plaintiff stage. Investors who purchased AZN stock or other securities between May 21, 2020 and November 20, 2020 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/AstraZeneca to submit their information. Investors may also email investors@tenlaw.com or call 617-531-3917.
FOR MORE INFORMATION: www.tenlaw.com/cases/AstraZeneca
The complaint alleges that AstraZeneca and its senior executives misrepresented facts regarding AstraZeneca's ongoing AZD1222 clinical trials and concealed problems that had arisen in the trials, including a dosing error which had been discovered by AstraZeneca early on but was not disclosed to investors.
Interested AstraZeneca investors have until March 27, 2021 to retain counsel and apply to be a lead plaintiff if they are interested to do so. Investors do not need to be a lead plaintiff in order to be a class member. A lead plaintiff acts on behalf of all other investor class members in managing the class action. If investors choose to take no action, they can remain an absent class member. The class has not yet been certified. Until certification occurs, investors are not represented by an attorney.
FOR MORE INFORMATION: www.tenlaw.com/cases/AstraZeneca
Thornton Law Firm's securities attorneys are highly experienced in representing investors in recovering damages caused by violations of the securities laws. Its attorneys have established track records litigating securities cases in courts throughout the country and recovering losses on behalf of investors. This may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
CONTACT:
Thornton Law Firm LLP
1 Lincoln Street
State Street Financial Center
Boston, MA 02111
www.tenlaw.com/cases/AstraZeneca
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/76225
